ALGS Stock Summary and Trading Ideas (Aligos Therapeutics | NASDAQ:ALGS)

Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Aligos Therapeutics trades on the NASDAQ stock market under the symbol ALGS.

As of February 19, 2026, ALGS stock price climbed to $7.12 with 24,160 million shares trading.

ALGS has a beta of 2.38, meaning it tends to be more sensitive to market movements. ALGS has a correlation of 0.13 to the broad based SPY ETF.

ALGS has a market cap of $43.81 million. This is considered a Sub-Micro Cap stock.

Last quarter Aligos Therapeutics reported $741,000 in Revenue and -$3.04 earnings per share. This beat revenue expectation by $241,000 and missed earnings estimates by -$1.00.

In the last 3 years, ALGS traded as high as $46.80 and as low as $3.76.

The top ETF exchange traded funds that ALGS belongs to (by Net Assets): VTI, VXF, AVSC, DCOR.

ALGS has underperformed the market in the last year with a return of -68.8%, while the SPY ETF gained +13.1%. In the last 3 month period, ALGS fell short of the market, returning -10.1%, while SPY returned +4.0%. However, in the most recent 2 weeks ALGS has outperformed the stock market by returning +0.7%, while SPY returned -0.2%.

ALGS support price is $6.31 and resistance is $7.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALGS shares will trade within this expected range on the day.